SMAD5, a transducer of TGF-beta/BMP inhibitory signals and a tumor suppress
or candidate, localizes to the region of invariant loss in human myeloid ne
oplasms, on chromosome 5q31.1. Recent evidence indicates a gene-dosage effe
ct along the TGF-beta/BMP signaling pathways. We have identified a novel tr
anscript. designated DAMS, whose 3' exonic sequences contain in part an alt
ernate 5' exon of SMAD5, in the antisense orientation. Expressed sequenced
tags (ESTs) for DAMS are found in fetal tissues (heart, adrenal glands, and
total fetus) and pancreatic tumor cDNA libraries. In contrast to SMAD5, DA
MS expression is not readily detectable in adult and fetal tissues. Semiqua
ntitative PCR suggests that the stoichiometry between SMAD5 and DAMS transc
ripts ranges between 15 and 120 in normal and malignant hematopoietic cells
. The findings raise the possibility that DAMS may be a fail-safe mechanism
for precise regulation of SMAD5 transcript levels that may be critical in
maintaining normal homeostasis. (C) 1999 Academic Press.